April 8, 2024 in KVA1213 Publications

Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Thierra Guillaudeux, PhD, Chief Scientific Officer, Kineta Inc American Association of Cancer Research Annual Meeting | April 8, 2024

Read More
March 12, 2024 in Kineta Press Release

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

  Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts No dose limiting toxicities observed at any dose level Cleared ...

Read More
February 22, 2024 in Kineta Press Release

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

  SEATTLE, Feb. 22, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...

Read More
December 12, 2023 in KVA1213 Publications

A highly potent anti-VISTA antibody KVA12123 – a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Shawn Iadonato, Yulia Ovechkina, Kurt Lustig, Jessica Cross, Nathan Eyde, Emily Frazier, Neda Kabi, Chen Katz, Remington Lance, David Peckham, Shaarwari Sridhar, Carla Talbaux, Isabelle Tihista, Mei X ...

Read More